Welcome to Capitol Pain Institute



Genetic Basis for Opioid Sensitivity in Pain Treatments

August 20th, 2016|acute pain, Latest News, opioids|

Capitol Pain Institute (CPI) recently reported how the U.S. Food and Drug Administration (FDA) is addressing the worrisome rise in the misuse and addiction of opioid pain medications. Now, there is a new study out implicating a specific genetic variation the may be responsible for opioid sensitivity and how different patients will respond unequally to

CPI Concurs with FDA Warnings of Opioid Use

May 25th, 2016|advanced pain management, Latest News, opioids|

The U.S. Food and Drug Administration (FDA) recently announced class-wide safety labeling changes for immediate-release opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. We at the Capitol Pain Institute (CPI) concur with the FDA and its continuing effort

Load More Posts